MedTrace Logo

Cross Linking for Treatment of Corneal Infection

NCT00912509 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-11-22

Study results available
· View outcomes & findings →

Summary

This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal cross linking system to treat corneal infections.

Conditions

  • Infectious Keratitis

Interventions

DRUG

riboflavin

riboflavin 0.1% is applied every 2 minutes for 30 minutes

DEVICE

UVX Light

UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%

Sponsors & Collaborators

  • Cornea Research Foundation of America

    collaborator OTHER

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912509 on ClinicalTrials.gov